share_log

Piper Sandler Downgrades Fulgent Genetics to Neutral, Lowers Price Target to $40

Benzinga Real-time News ·  Dec 8, 2022 05:14

Piper Sandler analyst David Westenberg downgrades Fulgent Genetics (NASDAQ:FLGT) from Overweight to Neutral and lowers the price target from $65 to $40.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment